• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Study Shows New Mechanism For How Psychedelics Promote Plasticity

Jason Najum by Jason Najum
June 7, 2023
in Science
Reading Time: 2 mins read
A A
Science Feature: MindMed’s LSD Trial for ADHD

“New study shows psychedelics promote plasticity by directly binding to BDNF receptor Trk”

 

I’m not gonna lie, I had to Google “BDNF receptor”.

And “Trk”.

Yet despite my understandable ignorance, it seems like we’ve received interesting new research on how psychedelics bind to receptors in the brain. A new study published in Nature posits that psychedelics express their significant antidepressant and neuroplastic effects by binding to receptors of the molecule brain-derived neurotrophic factor (BDNF).

[bsa_pro_ad_space id=2]
ADVERTISEMENT

With the serotonin 5-HT2A receptor getting most of the attention in psychedelic science circles, this new data could potentially change how we study psychedelics and develop future compounds. The research also theorizes that the antidepressant effects gained from psychedelics could potentially be separated from the trippy hallucinations.

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

But I’ll stop before I put my layman’s foot in my mouth — and default to the experts and publishers of the research. See their quotes and tweets below explaining some of the results.

 

We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to TrkB with affinities 1,000-fold higher than those for other antidepressants, and that psychedelics and antidepressants bind to distinct but partially overlapping sites within the transmembrane domain of TrkB dimers.

Buy Lasix with Fast Shipping

 

In a feat of multidisciplinary research led by @castren_eero lab, we uncover a new mechanism for psychedelics w/therapeutic potential: TrkB binding mediates neuroplasticity & antidepressant effects of LSD & psilocin, independent of hallucinogenic action. https://t.co/AlxH9zDLaz🧵

— Rafael Moliner (@RafaelMoliner) June 5, 2023

 

TrkB binding affinities of conventional ADs are low. We now found psychedelics show different binding modes & have ~1000x higher affinities for TrkB than other ADs; this may explain their robust effects on plasticity as well as psychedelics’ faster & longer-lasting AD actions! 3/ pic.twitter.com/xXLa5Omq89

— Rafael Moliner (@RafaelMoliner) June 5, 2023

 

And some meme fun from the psychedelic science nerds.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

 

summary of current #psychedelic twitter pic.twitter.com/IjiQP7uE4S

— Balázs Szigeti (@psybalazs) June 6, 2023

 

Tags: receptorssciencestudy
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
Psychedelics in Dubai: Therapeutic Role of Psychedelics Explored at Conference in the Arab Region

Psychedelics in Dubai: Therapeutic Role of Psychedelics Explored at Conference in the Arab Region

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.